Beta bionics CEO Sean Saint sells $113,258 in company stock

Sean Saint, President and CEO of Beta Bionics, Inc. (BBNX), sold 5,641 shares of the company’s common stock on September 3, 2026. The transaction, executed pursuant to a Rule 10b5-1 trading plan adopted on September 5, 2025, totaled approximately $113,258.

The shares were sold at a weighted average price of $20.0778, with individual sale prices ranging from $20.00 to $20.1696. Following this transaction, Mr. Saint directly holds 398,429 shares of Beta Bionics common stock.

In other recent news, Beta Bionics reported its financial results for the second quarter of 2026, revealing a significant 38% increase in revenue, reaching $32 million. Despite this revenue growth, the company experienced a wider-than-expected loss, reporting a loss of 53 cents per share, compared to analyst expectations of a 34-cent loss per share. The company also noted an improvement in gross margins and reaffirmed its full-year outlook. In addition to these financial results, William Blair initiated coverage on Beta Bionics with a Market Perform rating. Analyst Steven Lichtman highlighted the company’s unique AID algorithm on the iLet insulin pump, which requires significantly less patient interaction, as a positive aspect. These recent developments provide investors with key insights into Beta Bionics’ current financial performance and market positioning.